First-year quality of life assessment of an intraarterial (radplat) versus intravenous chemoradiation phase III trial

Annemieke H. Ackerstaff, Alfons J M Balm, Coen R N Rasch, Jan Paul De Boer, Ruud Wiggenraad, Derk H F Rietveld, R. Theo Gregor, Robert Kröger, Frans J M Hilgers

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background. We report the results of a multicenter randomized phase III study, assessing quality of life (QOL) in intra-arterial (IA) versus standard intravenous (IV) chemoradiation in advanced head and neck cancer. Methods. Two hundred seven patients with inoperable stage IV disease - 152 men and 55 women; mean age, 55 years - were included in this study. The patients were treated with standard radiotherapy with 4 weekly IA or 3 weekly IV cisplatin infusions. The QOL assessments carried out were EORTC-C30, H&N35, and trial-specific questionnaires. Results. Overall QOL deteriorated in all patients during treatment, is gradually improving over 1 year. IA patients showed significantly less nausea and vomiting at week 7 (p <.001). IV patients were significantly more fatigued (p <.006). At 1 year, no significant difference in tube feeding was found. Voice quality slightly exceeded the pretreatment values at 1 year. Forty-two of 62 employed patients returned to work. Conclusion. During treatment, significantly fewer problems with nausea and vomiting occurred in IA than in IV patients. Both groups showed improved voicing and oral intake during follow-up, often exceeding pretreatment values at 1 year.

Original languageEnglish
Pages (from-to)77-84
Number of pages8
JournalHead and Neck
Volume31
Issue number1
DOIs
Publication statusPublished - 1 Jan 2009

Cite this

Ackerstaff, A. H., Balm, A. J. M., Rasch, C. R. N., De Boer, J. P., Wiggenraad, R., Rietveld, D. H. F., ... Hilgers, F. J. M. (2009). First-year quality of life assessment of an intraarterial (radplat) versus intravenous chemoradiation phase III trial. Head and Neck, 31(1), 77-84. https://doi.org/10.1002/hed.20937
Ackerstaff, Annemieke H. ; Balm, Alfons J M ; Rasch, Coen R N ; De Boer, Jan Paul ; Wiggenraad, Ruud ; Rietveld, Derk H F ; Gregor, R. Theo ; Kröger, Robert ; Hilgers, Frans J M. / First-year quality of life assessment of an intraarterial (radplat) versus intravenous chemoradiation phase III trial. In: Head and Neck. 2009 ; Vol. 31, No. 1. pp. 77-84.
@article{703b1d209cb3492e8a96196bfa69e3de,
title = "First-year quality of life assessment of an intraarterial (radplat) versus intravenous chemoradiation phase III trial",
abstract = "Background. We report the results of a multicenter randomized phase III study, assessing quality of life (QOL) in intra-arterial (IA) versus standard intravenous (IV) chemoradiation in advanced head and neck cancer. Methods. Two hundred seven patients with inoperable stage IV disease - 152 men and 55 women; mean age, 55 years - were included in this study. The patients were treated with standard radiotherapy with 4 weekly IA or 3 weekly IV cisplatin infusions. The QOL assessments carried out were EORTC-C30, H&N35, and trial-specific questionnaires. Results. Overall QOL deteriorated in all patients during treatment, is gradually improving over 1 year. IA patients showed significantly less nausea and vomiting at week 7 (p <.001). IV patients were significantly more fatigued (p <.006). At 1 year, no significant difference in tube feeding was found. Voice quality slightly exceeded the pretreatment values at 1 year. Forty-two of 62 employed patients returned to work. Conclusion. During treatment, significantly fewer problems with nausea and vomiting occurred in IA than in IV patients. Both groups showed improved voicing and oral intake during follow-up, often exceeding pretreatment values at 1 year.",
keywords = "Aadvanced stage, Chemoradiation, Hhead and neck cancer, Intra-arterial infusion, IV infusion, Quality of life",
author = "Ackerstaff, {Annemieke H.} and Balm, {Alfons J M} and Rasch, {Coen R N} and {De Boer}, {Jan Paul} and Ruud Wiggenraad and Rietveld, {Derk H F} and Gregor, {R. Theo} and Robert Kr{\"o}ger and Hilgers, {Frans J M}",
year = "2009",
month = "1",
day = "1",
doi = "10.1002/hed.20937",
language = "English",
volume = "31",
pages = "77--84",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley Subscription Services, Inc., A Wiley Company Hoboken",
number = "1",

}

Ackerstaff, AH, Balm, AJM, Rasch, CRN, De Boer, JP, Wiggenraad, R, Rietveld, DHF, Gregor, RT, Kröger, R & Hilgers, FJM 2009, 'First-year quality of life assessment of an intraarterial (radplat) versus intravenous chemoradiation phase III trial' Head and Neck, vol. 31, no. 1, pp. 77-84. https://doi.org/10.1002/hed.20937

First-year quality of life assessment of an intraarterial (radplat) versus intravenous chemoradiation phase III trial. / Ackerstaff, Annemieke H.; Balm, Alfons J M; Rasch, Coen R N; De Boer, Jan Paul; Wiggenraad, Ruud; Rietveld, Derk H F; Gregor, R. Theo; Kröger, Robert; Hilgers, Frans J M.

In: Head and Neck, Vol. 31, No. 1, 01.01.2009, p. 77-84.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - First-year quality of life assessment of an intraarterial (radplat) versus intravenous chemoradiation phase III trial

AU - Ackerstaff, Annemieke H.

AU - Balm, Alfons J M

AU - Rasch, Coen R N

AU - De Boer, Jan Paul

AU - Wiggenraad, Ruud

AU - Rietveld, Derk H F

AU - Gregor, R. Theo

AU - Kröger, Robert

AU - Hilgers, Frans J M

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background. We report the results of a multicenter randomized phase III study, assessing quality of life (QOL) in intra-arterial (IA) versus standard intravenous (IV) chemoradiation in advanced head and neck cancer. Methods. Two hundred seven patients with inoperable stage IV disease - 152 men and 55 women; mean age, 55 years - were included in this study. The patients were treated with standard radiotherapy with 4 weekly IA or 3 weekly IV cisplatin infusions. The QOL assessments carried out were EORTC-C30, H&N35, and trial-specific questionnaires. Results. Overall QOL deteriorated in all patients during treatment, is gradually improving over 1 year. IA patients showed significantly less nausea and vomiting at week 7 (p <.001). IV patients were significantly more fatigued (p <.006). At 1 year, no significant difference in tube feeding was found. Voice quality slightly exceeded the pretreatment values at 1 year. Forty-two of 62 employed patients returned to work. Conclusion. During treatment, significantly fewer problems with nausea and vomiting occurred in IA than in IV patients. Both groups showed improved voicing and oral intake during follow-up, often exceeding pretreatment values at 1 year.

AB - Background. We report the results of a multicenter randomized phase III study, assessing quality of life (QOL) in intra-arterial (IA) versus standard intravenous (IV) chemoradiation in advanced head and neck cancer. Methods. Two hundred seven patients with inoperable stage IV disease - 152 men and 55 women; mean age, 55 years - were included in this study. The patients were treated with standard radiotherapy with 4 weekly IA or 3 weekly IV cisplatin infusions. The QOL assessments carried out were EORTC-C30, H&N35, and trial-specific questionnaires. Results. Overall QOL deteriorated in all patients during treatment, is gradually improving over 1 year. IA patients showed significantly less nausea and vomiting at week 7 (p <.001). IV patients were significantly more fatigued (p <.006). At 1 year, no significant difference in tube feeding was found. Voice quality slightly exceeded the pretreatment values at 1 year. Forty-two of 62 employed patients returned to work. Conclusion. During treatment, significantly fewer problems with nausea and vomiting occurred in IA than in IV patients. Both groups showed improved voicing and oral intake during follow-up, often exceeding pretreatment values at 1 year.

KW - Aadvanced stage

KW - Chemoradiation

KW - Hhead and neck cancer

KW - Intra-arterial infusion

KW - IV infusion

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=58149494809&partnerID=8YFLogxK

U2 - 10.1002/hed.20937

DO - 10.1002/hed.20937

M3 - Article

VL - 31

SP - 77

EP - 84

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 1

ER -